Novo Nordisk’s “Super Ozempic” Trial Disappoints Again Novo Nordisk, a pharmaceutical giant known for its groundbreaking diabetes treatments, recently faced a setback with its highly anticipated next-generation drug, CagriSema. The company’s shares took a hit after the release of disappointing trial results that revealed CagriSema failed to outperform its competitor, Eli Lilly’s Mounjaro. The pharmaceutical […]
Tag: Eli Lilly
Back To Top